Hologic (HOLX) Updates Q1 Earnings Guidance
Hologic (NASDAQ:HOLX) updated its first quarter earnings guidance on Wednesday. The company provided earnings per share guidance of $0.55-0.57 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.58. The company issued revenue guidance of $800-815 million, compared to the consensus revenue estimate of $819.23 million.Hologic also updated its FY 2019 guidance to $2.38-2.42 EPS.
Several brokerages recently issued reports on HOLX. Piper Jaffray Companies cut their price target on shares of Hologic to $45.00 and set an overweight rating for the company in a report on Thursday. BidaskClub downgraded shares of Hologic from a strong-buy rating to a buy rating in a report on Thursday, October 25th. Morgan Stanley cut their price target on shares of Hologic from $47.00 to $44.00 and set an equal weight rating for the company in a report on Thursday, October 11th. Zacks Investment Research downgraded shares of Hologic from a hold rating to a sell rating in a report on Tuesday, October 9th. Finally, UBS Group began coverage on shares of Hologic in a report on Tuesday, October 9th. They set a neutral rating and a $44.00 price target for the company. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $44.29.
Shares of NASDAQ HOLX traded up $0.79 during trading on Thursday, reaching $42.05. The company had a trading volume of 183,040 shares, compared to its average volume of 1,934,144. Hologic has a 52 week low of $35.10 and a 52 week high of $45.09. The company has a market cap of $11.01 billion, a PE ratio of 20.79, a P/E/G ratio of 1.84 and a beta of 0.65. The company has a current ratio of 1.29, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12.
In other Hologic news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the transaction, the director now directly owns 167,701 shares of the company’s stock, valued at $6,630,897.54. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christiana Stamoulis sold 30,967 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $40.70, for a total transaction of $1,260,356.90. Following the completion of the transaction, the director now directly owns 66,006 shares of the company’s stock, valued at $2,686,444.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,207 shares of company stock valued at $1,948,992. Insiders own 0.79% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/11/08/hologic-holx-updates-q1-earnings-guidance.html.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: The risks of owning bonds
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.